Together, these studies establish design rules—including LAT1-privileged scaffolds, para-aryl astatination, α-methyl stabilization, and circulation modulation—that consistently yield high tumor-to-blood ratios and reproducible in vivo efficacy in LAT1+ models. This evidence concerns the gene SLC7A5 and neoplasm.